Company Overview and News
MUMBAI, March 28 (Reuters) - India's Bharat Petroleum Corporation Ltd (BPCL) plans to build a $3 billion petrochemical unit to serve the Mumbai region, a company official said, to profit from the country's expected surge in demand for petrochemicals as its economy expands.
3:30 pm Market Closing: Benchmark indices reversed some of previous day's gains amid sell-off in last hour of trade.
Shares of Hindustan Organic Chemicals (HOCL) locked at 5 percent upper circuit as company board will consider sale of Rasayani land to BPCL.
RPP Infra Projects has informed the exchanges that it has bagged an order from Karnataka State Police Housing (KSPH) and Infrastructure Development Corporation (IDCL) for ₹50.70 crore. The company has to build 192 police quarters in Kolar City and 156 quarters in Mysore under the Police Gruha 2020 scheme. The work has to be completed within 16 months, RPP Infra said in a statement to the exchanges.
State run Hindustan Organic Chemicals Ltd. was buzzing during Wednesday’s trade on the BSE. The stock breached upper circuit at Rs 25.20 with an increment of 5%.
Duty on imports from Bangladesh, Taiwan, South Korea, Indonesia, Pakistan and Thailand valid for 5 years
The Cabinet Committee on Economic Affairs, has approved a restructuring plan for Hindustan Organic Chemicals Ltd (HOCL)
The restructuring plan involves closing down the operations of all the non-viable plants at Rasayani unit of HOCL except Di-Nitrogen Tetroxide (N2O4) plant which is to be transferred to ISRO on as is where is basis, with about 20 acres of land and employees associated with the plant. The N2O4 plant is of strategic importance as it is the only indigenous source of N2O4 which is used as liquid rocket propellant by ISRO in the space launch vehicles.
The Cabinet Committee on Economic Affairs (CCEA) on Wednesday approved restructuring of state-run Hindustan Organic Chemicals Ltd. (HOCL) after it registered continuous losses since 2011-12 even as most of its plants have been shut down and salaries not being paid to the employees.
5m - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...